Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 164 participants.

Also called NCT05879276

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 164 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05879276
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05879276. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2027-03-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Acronym
EMPASHOCK
Condition
Cardiogenic Shock
Intervention (Drug)
Empagliflozin 10 MG
Lead sponsor
Central Hospital, Nancy, France (class: other)

Record details

Record id
cardio:ct-nct05879276
Content hash
8403ed852c52cf68787f5778a3e1774e2e8184543616c712e5b1f9efa8a8a9ab